Genera’s low false negatives
Wednesday, 15 October, 2008
Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.
Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.
But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.
Genera believes the results are very encouraging, although they are not yet conclusive.
For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.
Top 6 artificial sweeteners associated with accelerated brain aging
An eight-year study tracking brain health of 12,772 Brazilian adults has associated six sugar...
1500 Queensland women to help develop ovarian cancer screening test
Postmenopausal women between the ages of 50 and 74 with intact ovaries, and no prior history of...
A neuroscientist and biochemist's antiviral lightbulb moment
While studying how certain processes work inside the human brain, an Australian scientist...
